These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 38347465)

  • 1. Influence of metabolic state and body composition on the action of pharmacological treatment of migraine.
    Bruijn N; van Lohuizen R; Boron M; Fitzek M; Gabriele F; Giuliani G; Melgarejo L; Řehulka P; Sebastianelli G; Triller P; Vigneri S; Özcan B; van den Brink AM;
    J Headache Pain; 2024 Feb; 25(1):20. PubMed ID: 38347465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus.
    Rivera-Mancilla E; Al-Hassany L; Villalón CM; MaassenVanDenBrink A
    Front Neurol; 2021; 12():686398. PubMed ID: 34177788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications.
    Marichal-Cancino BA; González-Hernández A; Guerrero-Alba R; Medina-Santillán R; Villalón CM
    Expert Rev Neurother; 2021 Sep; 21(9):1035-1050. PubMed ID: 34388955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
    Villalón CM; Olesen J
    Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic syndrome and prevention of migraine headache].
    Takeshima T
    Brain Nerve; 2009 Oct; 61(10):1143-53. PubMed ID: 19882941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and prospective pharmacological targets in relation to antimigraine action.
    Mehrotra S; Gupta S; Chan KY; Villalón CM; Centurión D; Saxena PR; MaassenVanDenBrink A
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):371-94. PubMed ID: 18626630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications.
    de Vries Lentsch S; Rubio-Beltrán E; MaassenVanDenBrink A
    Maturitas; 2021 Mar; 145():73-77. PubMed ID: 33541566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women.
    Amundsen S; Øvrebø TG; Amble NM; Poole AC; Nordeng H
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1525-1535. PubMed ID: 27624901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are antimigraine drugs that influence CGRP levels justified?
    Piechal A; Domitrz I; Kurkowska-Jastrzębska I; Mirowska-Guzel D
    Pharmacol Rep; 2019 Aug; 71(4):624-635. PubMed ID: 31181379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
    Gupta S; Villalón CM
    Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimigraine medication use and associated health care costs in employed patients.
    Wu J; Hughes MD; Hudson MF; Wagner PJ
    J Headache Pain; 2012 Mar; 13(2):121-7. PubMed ID: 22127427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating rimegepant for the treatment of migraine.
    de Vries T; Al-Hassany L; MaassenVanDenBrink A
    Expert Opin Pharmacother; 2021 Jun; 22(8):973-979. PubMed ID: 33648385
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of herbal medicine for prevention and treatment of migraine.
    Chen Y; Wang S; Wang Y
    Phytother Res; 2022 Feb; 36(2):730-760. PubMed ID: 34818682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events.
    González-Hernández A; Marichal-Cancino BA; Villalón CM
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1223-1235. PubMed ID: 34535065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Obesity and Migraine in Women.
    Pavlovic JM; Vieira JR; Lipton RB; Bond DS
    Curr Pain Headache Rep; 2017 Aug; 21(10):41. PubMed ID: 28842821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
    Peroutka SJ
    Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal chemistry of antimigraine drugs.
    Tekes K; Szegi P; Hashemi F; Laufer R; Kalász H; Siddiq A; Ertsey C
    Curr Med Chem; 2013; 20(26):3300-16. PubMed ID: 23746273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.